Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market Size, Demand, Type & Applications, Market Status And Forecasts To 2026


Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.

Request For The Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/190

Market Dynamics
Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Market Taxonomy
This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma.

Key Features of the Study:
  • This report provides in-depth analysis of the global B-cell maturation antigen (BCMA) targeted therapies market and provides pipeline analysis for the same
  • It elucidates potential opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, impact analysis, key developments, and competitive landscape
  • It profiles leading players in the global B-cell maturation antigen (BCMA) targeted therapies market based on the following parameters – company overview, financial performance, product pipeline, geographical presence, and key developments

Detailed Segmentation:
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type:
    • Antibody Drug Conjugates
    • CAR-T Cells
    • Bispecific Antibodies
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication:
    • Acute Lymphoblastic Leukemia
    • Multiple Myeloma

High unmet needs by the recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market
The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options are available for patients with recurrent cancer and hence the BCMA targeted therapies provides breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma and will also cater to the current unmet needs for the treatment of relapsed or refractory myeloma, where the existing treatment modalities have proved to be clinically inefficient.
Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.


About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Comments

Post a Comment

Popular posts from this blog

Cough Suppressant Drugs Market Widespread Research and Fundamental study to 2026

A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market. Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and
Read more

Medical Disposables Market to Witness a Pronounce Growth by 2026

Medical disposables are products that are used in hospitals or in various medical fields for prevention of infections and for safety measures to meet the medical standards. The medical disposables are important to lower the risk of cross-contamination and infections that is a primary aim of healthcare professionals and governments globally. Medical disposables includes conventional syringes, disposable medical catheters, isolation gowns, procedure kits and trays, blood glucose tes t strips, and wound care products. The medical disposables are the essential component of every hospital and they have one time usage and need to be disposed after use. Medical disposables are used in surgery, drug and fluid delivery, wound management, diagnostic testing, patient examination, incontinence management, sterilization, and to reduce the discomfort of patient. The need of safety and prevention from infections for the various medical fields such as surgical wear, hygiene, anesthesia and ped
Read more

Idiopathic Pulmonary Fibrosis Treatment Market Evolving Industry Trends and key Insights by 2026

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease distinguished by progressive and irreversible reduction in lung function characterized by thickening and damaging of the walls of the air sacs (called alveoli). Common symptoms include, dry cough, gradual onset of shortness of breath, nail clubbing, and fatigue. Other symptoms are weight loss and muscle and joint pain. Further complications include, hypertension, heart failure, pulmonary embolism or pneumonia. Major factors causing damage to the lungs include, acid reflux from stomach, certain viruses such as Epstein Barr virus and herpes virus or environmental factors such as breathing in dust such as silica dust, asbestos fibers, hard metal dust, and coal dust. Treatments for idiopathic pulmonary fibrosis (IPF) include, oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplant. Prescribed antifibrotic drugs include, Pirfenidone and Nintedanib. Request For A Sample Copy Of This
Read more